DOI : 10.1055/s-00034924

Nuklearmedizin - NuclearMedicine

Issue 01 · Volume 64 · March 2025 DOI: 10.1055/s-015-61272


63. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin
Bremen, 02.–05.04.2025

Wissenschaftliche Leitung:
Prof. Dr. Kambiz Rahbar
Abstracts (HTML) Abstracts (PDF) List of Authors
V30
Kühnel, C; Köhler, A; Brachwitz, T; Seifert, P; Gühne, F; Aschenbach, R; Freudenberg, R; Freesmeyer, M; Drescher, R: Clinical Outcomes of Holmium-166 Radioembolization with Personalized Dosimetry in Hepatocellular Carcinoma Treatment
V32
Zeimpekis, K; Sari, H; Gözlügöl, N; Achangwa, N R; Shi, K; Schindewolf, M; Afshar-Oromieh, A; Rominger, A; Seifert, R: Y-90 post-radioembolization dosimetry comparison between SPECT and whole-body LAFOV PET/CT
V33
Noto, A M; Shen, X; Harbach, A; Zacherl, M; Resch, S; Rumiantcev, M; Liubchenko, G; Brendel, M; Böning, G; Unterrainer, L; Delker, A; Sheikh, G: Correlation between longitudinal dosimetry and PET follow-up as indicator for salivary gland toxicity after Lu-177-PSMA therapy
V34
Holzgreve, A; Delker, A; Ells, Z; Brosch-Lenz, J; Zhu, S; Lira, S; Nikitas, J; Grogan, T; Elashoff, D; Unterrainer, L; Dahlbom, M; Allen-Auerbach, M; Czernin, J; Calais, J: Studienprotokoll der laufenden FLEX-MRT Studie: Randomisierte Phase-2-Studie zur FLEXiblen und erweiterten Dosierung der [177Lu]Lu-PSMA-617 Molekularen RadioTherapie (FLEX-MRT) in Patienten mit mCRPC
V35
Trautwein, N; Brendlin, A; Mattke, M; Paulsen, F; Löwenheim, H; Zender, L; la Fougère, C; Dittmann, H: PSMA-targeted imaging and radioligand therapy of advanced adenoid cystic carcinomas and other salivary gland carcinomas
V36
Hardiansyah, D; Yousefzadeh-Nowshahr, E; Budiansah, I; Nemer, U; Riana, A; Kind, F; Beer, A; Meyer, P T; Glatting, G; Mix, M: Einzelzeitpunkt-Tumordosimetrie mit populationsbasierter Modellauswahl und nichtlinearer Mixed-Effects-Modellierung in der [177Lu]Lu-PSMA-617-Therapie
V37
Kind, F; Nemer, U; Brueggemann, K; Jilg, C A; Meyer, P T; Mix, M; Freitag, M: Prognostischer Wert der SUV-Dispersion im Gesamttumorvolumen in der PSMA-PET/CT vor [177Lu]PSMA-I&T-Radioligandentherapie
V38
Karimzadeh, A; Fütterer, C; Hansen, K; Heck, M; Tauber, R; D'alessandria, C; Weber, W; Eiber, M; Rauscher, I: External validation of baseline 68Ga-PSMA-11 PET-based prediction models using 18F-flotufolastat PET in patients with metastatic castration-resistant prostate cancer receiving 177Lu-labeled PSMA-targeted radioligand therapy
V39
Kassar, M; Zhao, X; Hong, J; Birindelli, G; Drobnjakovic, M; Morath, V; Afshar-Oromieh, A; Weber, W; Eiber, M; Rominger, A; Ziegler, S; Wendler, T; Navab, N; Wang, F; Guo, H; Shi, K: In Silico Investigation of the Influence of Microenvironmental Heterogeneity on Radioligand Therapy Efficacy in Prostate Cancer